Date: 2016-01-07
Type of information: R&D agreement
Compound: novel human therapeutic antibodies
Company: Kymab (UK) The University of Texas MD Anderson’s Oncology Research for Biologics and Immunotherapy Translation (ORBIT) unit (USA - TX)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism: monoclonal antibody
Disease:
Details: * On January 7, 2016, Kymab and The University of Texas MD Anderson’s Oncology Research for Biologics and Immunotherapy Translation (ORBIT) unit, announced a strategic cancer drug discovery and development alliance.
The alliance seeks to discover and develop novel human therapeutic antibodies to treat a variety of cancers.
The agreement will utilize each partner’s complementary skills, resources and capabilities to develop innovative new drugs for cancer. The collaboration will combine Kymab’s industry-leading antibody platform,Kymouse™ , in-house discovery and development experience together with MD Anderson’s novel target biology, clinical datasets, translational and clinical infrastructure to develop products to clinical proof of concept and ultimately for submission for FDA approval. The collaboration will focus on developing novel monoclonal antibodies as well as on identifying biomarkers for identification of responder populations. The agreement is for an initial period of five years.
Financial terms:
Latest news:
